APELLIS PHARMACEUTICAL

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

01 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

28 Feb 2025 07:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

24 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

20 Feb 2025 02:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

14 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

27 Jan 2025 16:00:00 By Nasdaq GlobeNewswire

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

13 Jan 2025 09:00:00 By Nasdaq GlobeNewswire

Apellis Announces Keli Walbert to Join the Board of Directors

10 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Dec 2024 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

27 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

12 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

05 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

26 Oct 2024 14:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

22 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

16 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

25 Sep 2024 07:00:00 By Nasdaq GlobeNewswire